BioCryst Pharmaceuticals Inc (BCRX) — Free Cash Flow Generation Index

Latest as of December 2025: 1.00x

BioCryst Pharmaceuticals Inc (BCRX) has a Free Cash Flow Generation Index of 1.00x as of December 2025. Free cash flow of $275.23 Million represents 1% of operating cash flow ($276.04 Million). See BCRX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

1.00x

Free Cash Flow / Operating CF

Free Cash Flow

$275.23 Million

USD

Operating Cash Flow

$276.04 Million

USD

Capital Expenditures

$802.00K

USD

BioCryst Pharmaceuticals Inc Free Cash Flow Generation Index (2025–2025)

Historical FCF Generation Index trend for BioCryst Pharmaceuticals Inc across 1 annual periods. Explore how well can BioCryst Pharmaceuticals Inc service its debt to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for BioCryst Pharmaceuticals Inc (2025–2025)

Year-by-year Free Cash Flow Generation Index for BioCryst Pharmaceuticals Inc. For the full company profile including market capitalisation, see market value of BioCryst Pharmaceuticals Inc.

Year	FCG Index	Free Cash Flow (USD)	Operating CF	Capital Expenditures	YoY Change
2025	0.99x	$327.41 Million	$329.88 Million	$2.47 Million	—

FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).